RxSight, Inc. (RXST) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. RxSight, Inc. is a commercial-stage medical technology company focused on the RxSight Light Adjustable Lens (LAL) system for cataract surgery. The company operates in a single segment and is headquartered in Aliso Viejo, California. As of July 31, 2026, there were 41,593,256 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $33.7 million | $33.6 million | $64.6 million | $71.5 million |
| Product Sales | $27.2 million | $33.6 million | $58.1 million | $71.5 million |
| License & Collaboration Revenue | $6.5 million | $0 | $6.5 million | $0 |
| Net Loss | $(12.1) million | $(11.8) million | $(28.0) million | $(20.0) million |
| Loss Per Share (Basic & Diluted) | $(0.29) | $(0.29) | $(0.68) | $(0.49) |
| Cash, Cash Equivalents & Short-Term Investments | $208.8 million (as of June 30, 2026) | |||
| Accumulated Deficit | $(689.0) million (as of June 30, 2026) | |||
| Product Gross Margin | 71.2% | 74.9% | 73.8% | 74.8% |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue remained flat quarter-over-quarter ($33.7M vs $33.6M) due to a significant offset between declining product sales and new collaboration revenue. Product sales decreased 19.0% ($6.4M) driven by lower unit sales of Light Delivery Devices (LDDs) and LALs, attributed to increased competition and competitive trialing.
- Collaboration Revenue: The company recognized $6.5 million in license and collaboration revenue in Q2 2026, stemming from a new agreement with Alcon Pharmaceuticals. This was a non-recurring item in the prior year.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 5.0% to $30.4 million, primarily due to higher professional services fees. Research and Development (R&D) expenses decreased 9.6% to $9.2 million due to reduced headcount and employee allocations.
- Liquidity: Cash and short-term investments decreased from $228.1 million at year-end 2025 to $208.8 million at June 30, 2026. Net cash used in operating activities for the six months ended June 30, 2026, was $20.4 million.
Guidance, Outlook, and Material Events
- Alcon Collaboration: On June 30, 2026, RxSight entered a License, Collaboration, and Development Agreement with Alcon to develop light-adjustable versions of Alcon's simultaneous vision intraocular lenses. Alcon paid a $60 million upfront cash payment (received July 1, 2026). $6.5 million was recognized as revenue immediately; $3.5 million is deferred; and $50 million is recorded as a refund liability contingent on the agreement not being terminated within 120 days.
- Leadership Transition: On July 13, 2026, the Board appointed Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz transitioned to Chief Medical Officer. Mr. Mottiwala received equity awards valued at $14.0 million.
- Outlook: Management expects to continue incurring net operating losses in the foreseeable future. They believe current cash resources are sufficient to fund operations for at least the next 12 months. The company anticipates revenue growth driven by commercial realignment initiatives and expanded utilization of the LAL.
- Risks: Significant risks include the contingent nature of the Alcon collaboration milestones, ongoing securities class action litigation regarding prior financial guidance, supply chain constraints, and the need to achieve profitability to sustain operations.
Investor Verification Checklist
- Refund Liability Status: Verify the status of the $50 million refund liability associated with the Alcon deal, which must remain outstanding for 120 days post-effective date to be retained.
- Product Sales Trend: Monitor the trajectory of LDD and LAL unit sales to determine if the 19% decline in product sales is a temporary fluctuation or a structural shift due to competition.
- Litigation Exposure: Review the status of the consolidated securities class action lawsuit (In re RxSight Securities Litigation) where the motion to dismiss was denied in May 2026.
- Collaboration Milestones: Track the feasibility and regulatory milestones required to trigger the potential $70 million and $40 million optional payments from Alcon.
- Cash Burn Rate: Assess the sustainability of the current cash position ($208.8M) against the operating cash burn of approximately $20.4M per six months.